| 尉佳林,余发全,何桂榕,栗 荣,杨 嫚.埃索美拉唑为基础的四联疗法对消化性溃疡患者幽门螺杆菌根除率、炎性因子及生活质量的影响[J].,2019,19(18):3585-3588 |
| 埃索美拉唑为基础的四联疗法对消化性溃疡患者幽门螺杆菌根除率、炎性因子及生活质量的影响 |
| Effect of Esomeprazole-based Quadruple Therapy on Helicobacter Pylori Eradication Rate, Inflammatory Factors and Quality of Life in Patients with Peptic Ulcer |
| 投稿时间：2019-02-05 修订日期：2019-02-28 |
| DOI：10.13241/j.cnki.pmb.2019.18.041 |
| 中文关键词: 埃索美拉唑 四联疗法 消化性溃疡 幽门螺杆菌 炎性因子 生活质量 |
| 英文关键词: Esomeprazole Quadruple therapy Peptic ulcer Helicobacter pylori Inflammatory factors Quality of life |
| 基金项目:兰州军区医药卫生科研计划项目（CLZ15JA161) |
|
| 摘要点击次数: 669 |
| 全文下载次数: 468 |
| 中文摘要: |
| 摘要 目的：探讨埃索美拉唑为基础的四联疗法对消化性溃疡（PU）患者幽门螺杆菌（ Hp ）根除率、炎性因子及生活质量的影响。方法：选取2016年3月~2018年11月间我院接收的117例PU患者，根据数表法将患者随机分为对照组（n=58）和研究组（n=59），对照组给予以奥美拉唑为基础的四联疗法治疗，研究组给予以埃索美拉唑为基础的四联疗法治疗，比较两组患者临床疗效、 Hp 根除率、炎性因子、生活质量及不良反应。结果：研究组治疗后总有效率为74.58%（44/59），高于对照组患者的53.45%（31/58）（P<0.05）。两组患者治疗后白介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）较治疗前降低，且研究组低于对照组（P<0.05）。研究组的 Hp 根除率高于对照组（P<0.05）。两组患者治疗后临床症状、心理情感、社交及任务完成评分均较治疗前升高，且研究组高于对照组（P<0.05）。两组不良反应发生率比较无统计学差异（P>0.05）。结论：埃索美拉唑为基础的四联疗法治疗PU，可有效改善炎性因子水平、 Hp 根除率和生活质量，疗效确切，安全性好，临床应用价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the Effect of Esomeprazole-based Quadruple Therapy on Helicobacter Pylori ( Hp ) Eradication Rate, Inflammatory Factors and Quality of Life in Patients with Peptic Ulcer (PU). Methods: 117 PU patients who were received in our hospital from March 2016 to November 2018 were selected, they were randomly divided into control group (n=58) and research group (n=59) according to the number table method. The control group was treated with omeprazole-based quadruple therapy, and the research group was treated with esomeprazole-based quadruple therapy. The clinical efficacy, eradication rate of Hp , inflammatory factors, Quality of life and adverse reactions were compared between the two groups. Results: The total effective rate of the research group was 74.58% (44/59) after 6 weeks of treatment, which was higher than 53.45% (31/58) of the control group (P<0.05). After 6 weeks of treatment, the levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) in the two groups were lower than those before treatment, and the research group were lower than that in the control group (P<0.05). The Hp Eradication Rate in the research group was higher than that in the control group (P<0.05). After 6 weeks of treatment, the clinical symptoms, psychological emotion, Social and Task completion scores of the two groups were higher than those before treatment, and the research group was higher than that of the control group (P<0.05). There was no difference in incidence of adverse reactions between the two groups (P>0.05). Conclusion: Esomeprazole-based quadruple therapy is effective in treating PU. It can effectively improve the level of inflammatory factors, the eradication rate of Hp and the quality of life. It has definite curative effect, good safety and high clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
